Blog

DEEP RESEARCH · LIGACHEM BIO/ADC

LigaChem Bio: A Leader in Next-Generation ‘Smart Bomb’ Cancer Drugs

A focused ADC report on ConjuAll™, LCB84, LCB14, and the funding implications of Orion's acquisition

Written: 2025-07-19 · Biotech/ADC platform analysis · Original Naver Blog post / Attached audio

Investment decisions are your own responsibility. This material is research and is not a recommendation to buy or sell.

0. Bottom line first

LigaChem Bio is positioned in the high-growth ADC oncology field with its ConjuAll™ platform. The key investment points are the $1.7 billion Janssen licensing deal for LCB84, LCB14's HER2-ADC clinical profile, and the R&D funding base created by Orion Group's acquisition.

1. ADCs combine antibody, linker, and payload

Official fact: The source explains ADCs as a combination of an antibody that finds cancer-cell antigens, a potent cytotoxic payload, and a linker that manages blood stability and intracellular release.

ADC operating modelDesigned to improve tumor selectivity and reduce normal-cell toxicity
AntibodyTarget recognition
LinkerStability and release
PayloadMMAE/PBD/MMAF cytotoxins
Cancer cellSelective delivery
The balance between efficacy and safety depends on all three components working together.

2. What differentiates ConjuAll™

PRECISION

Site-specific conjugation

The platform aims to attach linker-payloads to defined antibody sites, improving DAR uniformity and product quality.

SAFETY

Blood stability

The design seeks to reduce premature payload release and trigger release inside target cells.

SCALE

Manufacturability

Homogeneous production supports reproducibility and quality control in clinical and commercial stages.

3. Two core pipelines

PipelineTarget/structureKey point in the source
LCB84TROP2 ADCLicensed to Janssen in late 2023 for up to $1.7 billion, about KRW 2.24 trillion.
LCB14HER2 ADCThe most advanced candidate, aimed at commercialization in China and framed as a best-in-class biobetter.
CS5001/IKS03 and othersPartner pipelinesExpansion assets with CStone, Iksuda, and others that can validate the platform.

Official fact: The source cites China phase 1a/1b data for LCB14: ORR 53.7% and median PFS 15.5 months. It compares this with Enhertu's ORR of 54.3%, and notes grade 3 or higher neutropenia of 4.5% for LCB14 versus 17% for Enhertu.

4. Meaning of the Orion acquisition

Interpretation: Orion's acquisition is more than an ownership event. It gives LigaChem Bio a funding base to move from a licensing-centered model toward more self-directed development and commercialization. In biotech, cash runway determines strategic freedom.

5. Risks and watchpoints

  • The ADC field is becoming more competitive, so target, linker, and payload differentiation must keep showing up in clinical data.
  • LCB84 global development progress, Janssen's pace, LCB14 China commercialization, and safety reproducibility are key checkpoints.
  • Investors should watch whether Orion's capital support converts into actual R&D productivity.

Sources

Naver original